Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Jun 8;67(22):643-645.
doi: 10.15585/mmwr.mm6722a5.

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season

Lisa A Grohskopf, Leslie Z Sokolow, Alicia M Fry, Emmanuel B Walter, Daniel B Jernigan
Practice Guideline

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season

Lisa A Grohskopf et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Intranasally administered live attenuated influenza vaccine (LAIV) was initially licensed in the United States in 2003 as a trivalent formulation (LAIV3) (FluMist, MedImmune, LLC). Quadrivalent live attenuated influenza vaccine (LAIV4) (FluMist Quadrivalent, MedImmune) has been licensed in the United States since 2012 and was first available during the 2013-14 influenza season, replacing LAIV3. During the 2016-17 and 2017-18 influenza seasons, the Advisory Committee on Immunization Practices (ACIP) recommended that LAIV4 not be used because of concerns about low effectiveness against influenza A(H1N1)pdm09-like viruses circulating in the United States during the 2013-14 and 2015-16 seasons (1,2). On February 21, 2018, ACIP recommended that LAIV4 be an option for influenza vaccination of persons for whom it is appropriate for the 2018-19 season (3). This document provides an overview of the information discussed in the decision-making process leading to this recommendation. A description of methodology and data reviewed will be included in the background materials that will supplement the 2018-19 ACIP Influenza Recommendations, which will replace the 2017-18 ACIP influenza statement (2), and which will also contain guidance for the use of LAIV4.

PubMed Disclaimer

Conflict of interest statement

Emmanuel B. Walter reports grants from Novartis V&D, Novavax, and Merck & Co, outside the submitted work. No other conflicts of interest were reported.

References

    1. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2016–17 influenza season. MMWR Recomm Rep 2016;65(No. RR-5). 10.15585/mmwr.rr6505a1 - DOI - PMC - PubMed
    1. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2017–18 influenza season. MMWR Recomm Rep 2017;66(No. RR-2). 10.15585/mmwr.rr6602a1 - DOI - PMC - PubMed
    1. CDC. Review of effectiveness of live attenuated influenza vaccine. Presented to the Advisory Committee on Immunization Practices, February 21, 2018. Atlanta, GA: US Department of Health and Human Services, CDC; 2018.
    1. Belshe RB, Edwards KM, Vesikari T, et al. ; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685–96. 10.1056/NEJMoa065368 - DOI - PubMed
    1. Ashkenazi S, Vertruyen A, Arístegui J, et al. ; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;25:870–9. 10.1097/01.inf.0000237829.66310.85 - DOI - PubMed

Publication types